Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 May 7;48(3):609-619.
doi: 10.1093/schbul/sbac013.

Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Michael Davidson  1   2 , Jay Saoud  1 , Corinne Staner  3 , Nadine Noel  3 , Sandra Werner  3 , Elisabeth Luthringer  3 , David Walling  4 , Mark Weiser  5 , Philip D Harvey  6 , Gregory P Strauss  7 , Remy Luthringer  1
Affiliations
Randomized Controlled Trial

Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Michael Davidson et al. Schizophr Bull. .

Abstract

Background: This is a placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT2A, sigma2, and α1A-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. This trial follows a previous trial that demonstrated roluperidone superiority over placebo in a similar patient population.

Methods: Roluperidone 32 mg/day, roluperidone 64 mg/day, or placebo was administered for 12 weeks to 513 patients with schizophrenia with moderate to severe negative symptoms. The primary endpoint was the PANSS-derived Negative Symptom Factor Score (NSFS) and the key secondary endpoint was Personal and Social Performance scale (PSP) total score.

Results: NSFS scores were lower (improved) for roluperidone 64 mg compared to placebo and marginally missing statistical significance for the intent-to-treat (ITT) analysis data set (P ≤ .064), but reached nominal significance (P ≤ .044) for the modified-ITT (m-ITT) data set. Changes in PSP total score were statistically significantly better on roluperidone 64 mg compared to placebo for both ITT and m-ITT (P ≤ .021 and P ≤ .017, respectively).

Conclusions: Results of this trial confirm the potential of roluperidone as a treatment of negative symptoms and improving everyday functioning in patients with schizophrenia. Study registration: Eudra-CT: 2017-003333-29; NCT03397134.

Keywords: negative symptoms; schizophrenia; treatment.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Patients distribution.
Fig. 2.
Fig. 2.
PANSS Negative Symptoms Factor Score (Marder) change from baseline (MMRM) ITT population.
Fig. 3.
Fig. 3.
Personal Social Performance (PSP) total score change from baseline (MMRM) ITT population.
See this image and copyright information in PMC

References

    1. Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5:664–677. - PubMed
    1. Robertson BR, Prestia D, Twamley EW, Patterson TL, Bowie CR, Harvey PD. Social competence versus negative symptoms as predictors of real world social functioning in schizophrenia. Schizophr Res. 2014;160:136–141. - PMC - PubMed
    1. Szczypiński JJ, Gola M. Dopamine dysregulation hypothesis: the common basis for motivational anhedonia in major depressive disorder and schizophrenia? Rev Neurosci. 2018;29:727–744. - PubMed
    1. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645–692. - PubMed
    1. Kirkpatrick B. Developing concepts in negative symptoms: primary vs secondary and apathy vs expression. J Clin Psychiatry. 2014;75:30–37. - PubMed

Publication types

Associated data